FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      
           
This page is updated frequently with new Autoimmune Diseases-related patent applications. Subscribe to the Autoimmune Diseases RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Diseases RSS RSS


Date/App# patent app List of recent Autoimmune Diseases-related patents
02/26/15
20150057297
 Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions patent thumbnailnew patent Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital
02/26/15
20150056198
 Aberrant cell-restricted immunoglobulins provided with a toxic moiety patent thumbnailnew patent Aberrant cell-restricted immunoglobulins provided with a toxic moiety
Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.
02/26/15
20150056185
 Immunoglobulin constant region fc receptor binding agents patent thumbnailnew patent Immunoglobulin constant region fc receptor binding agents
Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore
02/19/15
20150051242
 Rafamycin analogs and methods for making same patent thumbnailRafamycin analogs and methods for making same
A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mtor inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Zhejiang Zylox Medical Device Co., Ltd.
02/19/15
20150051196
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150051178
 Estriol therapy for autoimmune and neurodegenerative diseases and disorders patent thumbnailEstriol therapy for autoimmune and neurodegenerative diseases and disorders
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California
02/19/15
20150050210
 Pharmaceutical formulation comprising bendamustine patent thumbnailPharmaceutical formulation comprising bendamustine
The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives.
Salmon Pharma Gmbh
02/12/15
20150045361
 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045324
 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity patent thumbnailNovel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.. .
Hanmi Science Co., Ltd
02/12/15
20150044244
 Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases patent thumbnailCombined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a na/k pump inhibitor, an antigen and a dna encoding the antigen.. .
Beijing Advanccine Biotechnology Co. Ltd.
02/12/15
20150044164

Methods of treating autoimmune diseases


Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation
02/12/15
20150044134

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami
02/05/15
20150038545

Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof


As well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (cns) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.. .
02/05/15
20150038538

Thiadiazolidinediones as gsk-3 inhibitors


The present invention relates to new thiadiazolidinediones of formula (i), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (gsk-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them..
Asd Therapeutics Partners Llc
02/05/15
20150038480

Compounds that modulate autoimmunity and methods of using the same


The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same..
The Regents Of The University Of Colorado, A Body Corporate
02/05/15
20150037886

Treatment drug for autoimmune diseases and allergic diseases


The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-embigin antibody, particularly an anti-embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving th17 cell, and a cytotoxic agent to th17 cell. In addition, an agent for detection of th17 cell, which contains an anti-embigin antibody, a convenient detection method of th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a th17 cell selective manner, which uses an anti-embigin antibody, and a drug delivery system to th17 cell are provided..
Sumitomo Dainippon Pharma Co., Ltd.
01/29/15
20150031706

Novel compound useful for the treatment of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..
01/29/15
20150031671

Novel compound useful for the treatment of degenerative and inflammatory diseases


This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
01/22/15
20150023976

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/15/15
20150018336

Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
01/15/15
20150018329

Pharmaceutically active pyrazolo-triazine derivatives


The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
01/15/15
20150017164

Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.
01/15/15
20150017132

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl
01/08/15
20150011767

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010588

Aromatic-cationic peptides and uses of same


The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, and inhibition of apoptosis and necrosis to treat, prevent or ameliorate the symptoms of autoimmune diseases or condition..
Cornell University
01/01/15
20150004178

Anti-human sema4a antibodies useful to treat disease


Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
12/25/14
20140378475

Substituted tetrahydrocarbazole and carbazole carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378446

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
12/25/14
20140377291

Glycosphingolipids for use in modulating immune responses


Provided herein are sphingolipid compounds that are useful for activating natural killer t cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer t cells.
President And Fellows Of Harvard College
12/18/14
20140371272

Therapeutic compounds


The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
Regents Of The University Of Minnesota
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/18/14
20140371198

Novel compounds useful for the treatment of metabolic and inflammatory diseases


These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .
12/18/14
20140370044

Modified epitopes for boosting cd4+ t-cell responses


The present invention relates to immunogenic peptides comprising a t-cell epitope. Said peptides are modified such that cd4+ t-cell responses are obtainable that are much stronger than the cd4+ t-cell responses obtained with the same peptides not comprising said modification.
Life Sciences Research Partners Vzw
12/18/14
20140370033

Methods for the treatment or prevention of systemic sclerosis


The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that ssc patients have an elevated plasma level of cxcl4.
Stichting Katholieke Universiteit
12/18/14
20140369966

Preventive and/or ameliorative agent for diseases, stamina enhancement agent, anti-fatigue agent, and pharmaceutical and food and drink using them


A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria.
Tfk Co., Ltd.
12/11/14
20140364607

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
12/11/14
20140364604

Method of making monomethyl fumarate


Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis..
12/11/14
20140364438

Triazolopyridine derivatives as a tyrosine kinase inhibitor


Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
12/11/14
20140364401

Antispasmodic 1,2-diols and 1,2,3-triols


The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/11/14
20140363829

Method for increasing specificity of diagnostic tests for autoimmune diseases


Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a dfs70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed..
12/11/14
20140363497

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/04/14
20140357690

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
12/04/14
20140357614

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor


Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .
12/04/14
20140357599

Novel urea and thiourea derivatives


The present application discloses compounds of formula (i) wherein x is ═o, ═s, ═nh, ═noh and ═no-me; a is —c(═o)—, —s(═o)2—, —c(═s)— and p(═o)(r5)—; b is, —o—, —(ch2)3-6—, and o—(ch2)2-5—; d is, —o—, —cr7r8— and —nr9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; r1 is opt.sub. Heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof.
11/27/14
20140349987

Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases


The invention provides modulators for the orphan nuclear receptor rorγ and methods for treating rorγ mediated diseases by administrating these novel rorγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of formula (1) and the enantiomers, diastereomers, n-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof..
11/27/14
20140349311

Therapeutic agent for autoimmune diseases or allergy, and screening for the therapeutic agent


Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between sema3a and a neuropilin-1/plexin-a1 heteroreceptor. The substance includes, for example, a sema3a neutralizing antibody, a neuropilin-1 neutralizing antibody, or a soluble neuropilin-1 or derivative thereof.
11/20/14
20140343150

Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases


A phytosphingosine derivative of chemical formula ia or ib, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like..
11/20/14
20140341935

Mutant hsp70i to prevent autoimmune disease


A vaccine and method of treatment suitable for treating autoimmune diseases, such as vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 dna sequence encoding the peptide..
11/20/14
20140341933

Use of pdl1 expressing cells to convert t cells into regulatory t cells


The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
11/20/14
20140341921

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
11/13/14
20140336206

Inhibitors of bruton's tyrosine kinase


Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
11/13/14
20140336203

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
11/13/14
20140336151

Silicon-containing fumaric acid esters


The present invention is directed to silicon-containing fumaric acid esters of the formulae i-iv. The silicon-containing fumaric acid esters of formulae i-iv are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases.
11/13/14
20140335108

Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases


The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
11/13/14
20140335075

Immunoglobulin constant region fc receptor binding agents


Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
11/06/14
20140329900

Small molecule inhibitors of stat3 with anti-tumor activity


The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
11/06/14
20140329815

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
11/06/14
20140328836

Her2/neu-specific antibodies and methods of using same


This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
11/06/14
20140328807

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
10/23/14
20140315917

Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities


Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
10/23/14
20140314866

Materials and methods for modulating immune responses


The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
10/23/14
20140314764

Bi-specific antibodies for medical use


A bispecific antibody format devoid of an active fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on b-cells, for use in the treatment or prevention of b cell mediated autoimmune diseases.. .
10/23/14
20140314710

Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment


A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
10/16/14
20140308281

Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates


The invention concerns antibodies directed against cd127, i.e. The alpha chain of the receptor for interleukin7 (il-7), especially the receptor for human il-7 expressed on human cells (designated human il-7r alpha or il-7ra) or the tslp receptor.
10/16/14
20140308244

Combination therapy for treatment of inflammatory demyelinating disease


Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more second compounds, in one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin b, dimethyl fumarate (dmf, also referred to as bg-12) and fingolimod (gilenya)..
10/16/14
20140308238

Immunomodulating compositions and methods of use thereof


The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention are enriched for o-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
10/16/14
20140308209

Soluble mediator


The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
10/09/14
20140303140

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein r1a, r1b, r2, r4, r5, r6a, r6b, r7, r8, w, x, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..
10/09/14
20140302070

Novel pd1 isoforms, and uses thereof for potentiating immune responses


In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140302058

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases


The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..


Popular terms: [SEARCH]

Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.5904

3902

74 - 0 - 71